HA-100
Based on 1 publication(s) in Google Scholar
HA-100 is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK inhibitor.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.87%
- CAS 番号: 84468-24-6
- 分子式: C13H15N3O2S
- 分子量:277.34
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-12041
SP600125JNK Inhibitor -
HY-10254
MirdametinibMEK Inhibitor -
HY-10432
A 83-01ALK4/5/7 Inhibitor -
HY-18980
RottlerinPKC Inhibitor -
HY-12048
Chelerythrine chlorideBcl-2 Family Inhibitor -
HY-N6791
KT5823PKG Inhibitor -
HY-15979
H-89PKA Inhibitor -
HY-13689
Go 6983PKC Inhibitor -
HY-12306
8-Bromo-cAMP sodium saltPKA Activator -
HY-15141
StaurosporinePKC/PKA Inhibitor -
HY-101047
D-erythro-SphingosinePKC Inhibitor -
HY-B0764
Bucladesine sodiumcAMP Analog
MedChemExpress（MCE）の使用を引用している文献 HA-100
More
生物活性
製品説明
IC50 & Target
[1]|
PKC 12 μM (IC50) |
PKG 4 μM (IC50) |
PKA 8 μM (IC50) |
MLCK 240 μM (IC50) |
PKC 6.5 μM (Ki) |
MLCK 61 μM (Ki) |
体外実験
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 84468-24-6
-
性状 Solid
-
分子量 277.34
-
分子式 C13H15N3O2S
-
Color White to off-white
-
SMILES
O=S(C1=CC=CC2=C1C=CN=C2)(N3CCNCC3)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Am J Physiol Cell Physiol
cGMP-dependent protein kinase II determines β-catenin accumulation that is essential for uterine decidualization in mice. [Abstract]2019 Dec 1;317(6):C1115-C1127. PMID: 31509448
溶剤 & 溶解度
体外:
DMSO : 150 mg/mL (540.85 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.01 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.01 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Hagiwara M, et al. Selective modulation of calcium-dependent myosin phosphorylation by novel protein kinase inhibitors, isoquinolinesulfonamide derivatives. Mol Pharmacol. 1987 Jul;32(1):7-12. [Content Brief]
[2]. Yu J, et, al. Efficient feeder-free episomal reprogramming with small molecules. PLoS One. 2011 Mar 1;6(3):e17557. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6057 mL | 18.0284 mL | 36.0568 mL | 90.1421 mL |
| 5 mM | 0.7211 mL | 3.6057 mL | 7.2114 mL | 18.0284 mL | |
| 10 mM | 0.3606 mL | 1.8028 mL | 3.6057 mL | 9.0142 mL | |
| 15 mM | 0.2404 mL | 1.2019 mL | 2.4038 mL | 6.0095 mL | |
| 20 mM | 0.1803 mL | 0.9014 mL | 1.8028 mL | 4.5071 mL | |
| 25 mM | 0.1442 mL | 0.7211 mL | 1.4423 mL | 3.6057 mL | |
| 30 mM | 0.1202 mL | 0.6009 mL | 1.2019 mL | 3.0047 mL | |
| 40 mM | 0.0901 mL | 0.4507 mL | 0.9014 mL | 2.2536 mL | |
| 50 mM | 0.0721 mL | 0.3606 mL | 0.7211 mL | 1.8028 mL | |
| 60 mM | 0.0601 mL | 0.3005 mL | 0.6009 mL | 1.5024 mL | |
| 80 mM | 0.0451 mL | 0.2254 mL | 0.4507 mL | 1.1268 mL | |
| 100 mM | 0.0361 mL | 0.1803 mL | 0.3606 mL | 0.9014 mL |
HA-100 関連分類
HY-100984 関連分類
Powered by Bioz